Romonia Renee Reams

Professor

Florida A&M University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Objectives Black/African American (B/AA) pancreatic ductal adenocarcinoma (PDAC) patients have worse clinical outcomes than White patients and are underrepresented in genomic databases. We aimed to expand our understanding of the PDAC somatic landscape from a diverse cohort. Materials and Methods Formalin-fixed paraffin-embedded specimens from 24 surgically resected PDAC cases were collected, with self-reported race/ethnicity. Whole exome sequencing was performed on malignant and benign tissue. Bioinformatics analysis included deduction of genetic ancestry and somatic mutational analysis, with comparisons to public datasets. Results Out of 24 cases, 17 identified as B/AA race; genetic ancestry analysis confirmed proportions of Sub-Saharan African ancestry greater than 47%. The most commonly mutated genes included KRAS , TP53 , SMAD4 , and CDKN2A . Comparison of mutations in our cohort versus publicly available, predominantly White datasets showed higher mutation frequencies of ATM, RREB1, BRCA1/2, KDM6A, ARID1A, BRAF, and MYC ( P < 0.04). When cohorts were combined and analyzed by race, no mutation frequencies differences were observed, including KRAS . Conclusions Genomic analysis of PDAC tumors from B/AA and White patients demonstrate similarities in mutation frequencies. Larger studies are needed to further understand molecular characterizations across continental subpopulations. This study provides further rationale for equitable representation of diverse patients in genomic databases and clinical trials.

Year:

2025

Aim Availability of pancreatic ductal adenocarcinoma (PDAC) xenografts is a recognized medical research need. Patient-derived xenograft (PDX) mouse models are a valuable tool for studying PDAC, as they preserve the molecular, histological, and often stromal features of the primary tumor. However, access to PDX technologies is nationally limited, particularly at Historically Black Colleges and Universities (HBCUs). We aimed to establish a self-sustained PDX biorepository at Florida A&M University (FAMU), a HBCU, through a partnership with two NCI-designated cancer centers and the CaRE 2 Health Center. Methods FAMU faculty and trainees received training in xenograft implantation, tumor excision, cryopreservation, and biorepository management. The University of Florida shipped frozen tumor tissues from two PDAC patients to FAMU; one was implanted at FAMU and serially passaged across generations for experimental needs and to produce reproducible early generation PDX. Trainees gained experience in both laboratory and translational workflows and participated in documenting standard operating procedures for sustaining the biorepository. Results Engraftment success was observed across murine generations (G): G0 (66%, mean volume 196.5 mm 3 ), G1 (50%, 283.0 mm 3 ), G2 (60%, 321.4 mm 3 ), and G3 (80%, 416.3 mm 3 ). All viable tumors were cryopreserved and archived in FAMU’s newly established PDX biorepository. The repository now supports two active PDAC projects focused on drug response and biomarker discovery and can passage the second PDAC tumor. Conclusion Our successful collaboration and transfer of advanced cancer modeling technology to a HBCU strengthens FAMU’s institutional research capacity. The collaboration also offers translational cancer research training, preparing trainees for careers in oncology medicine and biomedical science.

Year:

2025

Year:

2025

Black individuals are disproportionately burdened by prostate cancer compared with White individuals. The mitochondrion is an untapped source for prostate cancer biomarkers, and previous work has shown that altered mitochondrial DNA (mtDNA) copy number is linked to mitochondrial dysfunction and tumorigenesis. We assess whether mtDNA copy number is altered in patients with and without prostate cancer in a racially specific manner. Circulating cell-free mtDNA copy number from plasma and mtDNA copy number from white blood cells (WBC) were measured in 199 patients undergoing biopsy (50:50 White cases/controls and 50:49 Black cases/controls). mtDNA copy number was determined via Droplet Digital PCR. Logistic regressions tested associations between mtDNA and prostate cancer by race. The AUC was compared between covariate-only models and models with mtDNA. In both plasma and WBCs, mtDNA copy number was significantly increased in cases compared with controls in White patients, but not in Black patients. Interestingly, Black controls had higher mtDNA copy number levels than White controls. Multivariable analysis revealed significant associations of plasma mtDNA and WBC mtDNA with prostate cancer for White patients only. Elevated mtDNA copy number was more accurate in predicting prostate cancer in White patients than in Black patients. Higher mtDNA copy number levels were associated with prostate cancer in both Black and White patients. Plasma mtDNA may be more accurate than WBC mtDNA in predicting prostate cancer incidence in Black men. Overall, Black controls had higher mtDNA copy number levels than White controls, suggesting mtDNA copy number may be implicated in prostate cancer health disparities. Prevention Relevance: Our study shows that mtDNA copy number is a significant predictor of prostate cancer in White individuals, suggesting its potential use in early detection and prevention strategies. The absence of this association in Black individuals highlights the need for race-specific biomarkers in prostate cancer prevention efforts.

Year:

2025

Supplemental Table S3 shows univariable and multivariable multinomial logistic regression models for testing the association between mtDNA copy number and prostate cancer grade stratified by race

Year:

2025

Supplemental Figure S3 shows receiver operating characteristic (ROC) curves between univariable models adjusted for PSA (log-transformed) only, Plasma mtDNA only, and WBC mtDNA only, stratified by Black and White individuals.

Year:

2025

Cancer health disparities that exist in the Black or African American and Hispanic or Latino/x communities are scientific challenges, yet there are limited team science approaches to mitigate these challenges. This article's purpose is to evaluate the team science collaborations of the National Institutes of Health‐funded Florida‐California Cancer Research, Education & Engagement (CaRE 2 ) Center partnership underscoring the inclusion of multidisciplinary team members and future under‐represented minority (URM) cancer researchers. To understand our collaborative efforts, we conducted a social network analysis (SNA) of the CaRE 2 Center partnership among University of Florida, Florida A&M University, and University of Southern California with data collected via the dimensions.ai application programming interface. We downloaded metadata for all publications associated with dimensions.ai IDs. The CaRE 2 collaboration network increased over time as evidenced by accruing more external collaborators and more publishing of collaborative works. Degree centrality of key personnel was stable in each wave of the networks. CaRE 2 key personnel averaged a total of 60.8 collaborators in 2018–2019 (SD = 57.4, minimum = 3, maximum = 221), and 65.8 collaborators in 2020–2021 (SD = 56.06, minimum = 4, maximum = 222). Betweenness was largely stable across all groups and waves. We observed a steady decline in transitivity, the probability that a pair of CaRE 2 co‐authors shared a third co‐author, from 0.74 in 2018 to 0.47 in 2022. The SNA findings suggest that the CaRE 2 Center partnership's publications show growth in team science collaborations with the inclusion of multidisciplinary team members from the three partner institutions and future URM cancer researchers who were mentored as trainees and early‐stage investigators.

Year:

2024

Year:

2023

Collaborators (10)

Jose Aparicio

University of Southern California Keck School of Medicine

UNITED STATES
View details

Kelvin Yen

Research Associate Professor

University of Southern California

UNITED STATES
View details

Li-Ming Su

Professor and Chair

University of Florida College of Medicine

UNITED STATES
View details

Diana J. Wilkie

University of Florida College of Nursing

UNITED STATES
View details

Nazarius Lamango

Professor

Florida A&M University College of Pharmacy and Pharmaceutical Sciences

UNITED STATES
View details

Thomas Smith

Assistant Professor

University of Mississippi

UNITED STATES
View details

Edward Agyare

Professor and Director

Florida A&M University

UNITED STATES
View details

Sulma I Mohammed

Professor

Purdue University

UNITED STATES
View details

Mirajul Islam

Teaching Assistant

St. Jude Children's Research Hospital

UNITED STATES
View details

Pinchas Cohen

Dean

University of Southern California

UNITED STATES
View details